# Trial of Adjuvant Sutent for Patients With High Risk Urothelial Carcinoma After Neoadjuvant Chemotherapy and Cystectomy

> **NCT01042795** · PHASE2 · TERMINATED · sponsor: **University of Michigan** · enrollment: 7 (actual)

## Conditions studied

- Urothelial Carcinoma
- Bladder Cancer

## Interventions

- **DRUG:** Sunitinib

## Key facts

- **NCT ID:** NCT01042795
- **Lead sponsor:** University of Michigan
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-09
- **Primary completion:** 2012-04
- **Final completion:** 2013-01
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** Study closed due to poor accrual
- **Last updated:** 2017-06-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01042795

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01042795, "Trial of Adjuvant Sutent for Patients With High Risk Urothelial Carcinoma After Neoadjuvant Chemotherapy and Cystectomy". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01042795. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*